CCK as a treatment for pancreatic acinar cell carcinoma

Overview

About this study

The purpose of this study is to learn more about the function of CCK receptor in human ACC cells and test the effect of high concentration CCK on ACC cells.  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria

  • Any adult patients who had diagnosis of ACC and tissue available at Mayo Clinic 
  • Will recruit adult ACC patients who sign the consent form to participate in the study

Control cases

  • Non-ACC patients who have pancreas tissue available including pancreas cystic lesions, chronic pancreatitis, and normal adjacent pancreatic cancer tissue.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Yan Bi, M.D., Ph.D.

Open for enrollment

Contact information:

Yan Bi M.D., Ph.D.

(904) 953-6970

Bi.Yan@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Yan Bi, M.D., Ph.D.

Contact us for the latest status

Contact information:

Lizhi Zhang M.D.

(507)293-1393

Zhang.Lizhi@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20348155

Mayo Clinic Footer